Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients

Table 3

Adverse events of everolimus (EVL) during 12 months of Follow-up¹.

Adverse event	1.0 mg of EVL (𝑁=51)	1.5 mg of EVL (𝑁=56)	P value
Patients who discontinued everolimus treatment before 12 months
Death	0	2 (3.6)	0.272
Graft loss	0	0	>0.999
Lost to follow-up	0	0	>0.999
Adverse events leading to EVL discontinuation	12 (23.5)	19 (33.9)	0.166
Infection	6 (11.8)	1 (1.8)	0.043
Edema and/or dyspnoe(total)	5 (7.8)	10 (17.9)	0.105
Lingual edema	0	1 (1.8)	0.523
Diarrhea	0	1 (1.8)	0.523
Epitaxis	1 (2.0)	2 (3.6)	0.523
Cytopenia	0	4 (7.1)	0.048
Urticaria	0	1 (1.8)	0.523
All patients	22 (43.1)	35 (62.5)	0.054
Rejection	5 (9.8)	3 (5.4)	0.307
All adverse events
Infection	10 (19.6)	2 (3.6)	0.009
Edema and/or dyspnoe (total)	6 (11.8)	19 (33.9)	0.011
Lingual edema	0	2 (3.6)	0.225
Diarrhea	0	3 (5.4)	0.105
Epitaxis	1 (2.0)	0	0.523
Cytopenia	0	5 (8.9)	0.022
Urticaria	0	1 (1.8)	0.523

¹Data are presented as numbers and percentages.